We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
+$172M
Cap. Flow
+$37.5M
Cap. Flow %
5.59%
Top 10 Hldgs %
63.01%
Holding
164
New
62
Increased
39
Reduced
20
Closed
34

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.49M
2
CNVS icon
Cineverse
CNVS
+$6.05M
3
SHIP icon
Seanergy Maritime Holdings
SHIP
+$5.68M
4
RMTI icon
Rockwell Medical
RMTI
+$5.66M
5
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$5.55M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.6M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.7M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$2.89M
4
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
+$2.88M
5
ALNA
Allena Pharmaceuticals
ALNA
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 12.1%
2 Technology 0.73%
3 Industrials 0.54%
4 Communication Services 0.41%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
76
CALL
Amarin Corp
AMRN
$297M
$643K 0.1%
+254
New +$30.4K
PLUR icon
77
Pluri
PLUR
$17M
$629K 0.09%
7,466
+3,754
+101% +$287K
LPCN icon
78
Lipocine
LPCN
$17.1M
$625K 0.09%
26,086
+25,236
+2,969% +$670K
SRPT icon
79
CALL
Sarepta Therapeutics
SRPT
$1.64B
$618K 0.09%
+44
New +$6.69K
ATXS
80
PUT
DELISTED
Astria Therapeutics
ATXS
$552K 0.08%
149
+70
+89% +$2.77K
PTE
81
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
$501K 0.07%
193
+185
+2,313% +$6.11K
XWEL icon
82
PUT
XWELL
XWEL
$8.95M
$497K 0.07%
126
+109
+641% +$6.38K
ODT
83
PUT
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$475K 0.07%
354
-121
-25% -$3.43K
BGMS
84
Bio Green Med Solution Inc
BGMS
$4.86M
$458K 0.07%
+35
New +$523K
CRDF icon
85
CALL
Cardiff Oncology
CRDF
$63M
$450K 0.07%
+317
New +$2.09K
ADTX
86
DELISTED
ADITXT INC
ADTX
– –
0
– –
XLV icon
87
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
$422K 0.06%
4,000
-101,280
-96% -$10.7M
PAVMZ
88
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$364K 0.05%
436,973
-405,237
-48% -$386K
CYTK icon
89
CALL
Cytokinetics
CYTK
$10.6B
$340K 0.05%
157
– –
BSIN
90
Big Sky Industrial
BSIN
$58.6M
$333K 0.05%
+66,504
New +$352K
SCPH
91
DELISTED
scPharmaceuticals
SCPH
$316K 0.05%
42,407
-83,345
-66% -$651K
NXTP
92
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
$297K 0.04%
+6,729
New +$319K
LSTA icon
93
PUT
Lisata Therapeutics
LSTA
$9.93M
$293K 0.04%
+109
New +$3.45K
PHAS
94
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$279K 0.04%
79,470
+2,500
+3% +$10.1K
GNCA
95
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
$236K 0.04%
1,032
-1,094
-51% -$2.87K
PALI icon
96
Palisade Bio
PALI
$341M
$229K 0.03%
87
+61
+235% +$195K
AUPH icon
97
Aurinia Pharmaceuticals
AUPH
$1.95B
$200K 0.03%
13,544
-11,456
-46% -$166K
HEPA
98
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
$184K 0.03%
+1
New +$3.59K
ALT icon
99
Altimmune
ALT
$568M
$182K 0.03%
+13,800
New +$276K
HEPA
100
DELISTED
Hepion Pharmaceuticals
HEPA
$178K 0.03%
+57
New +$205K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sabby Management held 164 positions worth $670M, up 34% from $498M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $37.5M of net new capital in Q3 2020, opening 62 new positions and adding to 39 existing holdings. Its largest new stake was Cineverse: 243,797 shares worth $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 11% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Biogen, an estimated $16.6M trimmed.

  • Sabby Management's largest Q3 2020 buy was Cineverse: 243,797 shares worth $2.75M.
  • Sabby Management added most to AstraZeneca in Q3 2020, an estimated $6.49M increase.
  • Sabby Management's biggest Q3 2020 reduction was Biogen, cutting an estimated $16.6M.
  • Sabby Management fully exited Xeris Biopharma Holdings in Q3 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 63% of its $670M portfolio in Q3 2020.
  • Sabby Management opened 62 new positions and closed 34 in Q3 2020.
  • Sabby Management's portfolio value rose 34% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.